Evidence map›Paper›PMID 32659913›Full record

ArticleInternational journal of molecular sciences2020

Dual Leucine Zipper Kinase Is Constitutively Active in the Adult Mouse Brain and Has Both Stress-Induced and Homeostatic Functions.

Sunil Goodwani, Celia Fernandez, Paul J Acton, Virginie Buggia-Prevot, Morgan L McReynolds, Jiacheng Ma, Cheng Hui Hu, Mary E Hamby, Yongying Jiang, Kang Le and 3 more

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.6field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 21 citations in OpenAlex.

  1. Review
  2. Article
  3. White matter injury after brain ischemia.Experimental neurology · 2026
    Review
  4. Article
  5. Article
  6. Review
  7. The MAP3Ks DLK and LZK Direct Diverse Responses to Axon Damage in Zebrafish Peripheral Neurons.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2022
    Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Sunil GoodwaniThe Neurodegeneration Consortium, Therapeutics Discovery Division, University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA.ORCID 0000-0002-0666-4364
Celia FernandezThe Neurodegeneration Consortium, Therapeutics Discovery Division, University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA.
Paul J ActonThe Neurodegeneration Consortium, Therapeutics Discovery Division, University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA.
Virginie Buggia-PrevotThe Neurodegeneration Consortium, Therapeutics Discovery Division, University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA.
Morgan L McReynoldsThe Neurodegeneration Consortium, Therapeutics Discovery Division, University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA.
Jiacheng MaThe Neurodegeneration Consortium, Therapeutics Discovery Division, University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA.ORCID 0000-0002-4767-6150
Cheng Hui HuThe Neurodegeneration Consortium, Therapeutics Discovery Division, University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA.ORCID 0000-0001-9623-8766
Mary E HambyThe Neurodegeneration Consortium, Therapeutics Discovery Division, University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA.ORCID 0000-0002-6782-1853
Yongying JiangInstitute for Applied Cancer Science, Therapeutics Discovery Division, University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA.
Kang LeInstitute for Applied Cancer Science, Therapeutics Discovery Division, University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA.
Michael J SothInstitute for Applied Cancer Science, Therapeutics Discovery Division, University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA.
Philip JonesInstitute for Applied Cancer Science, Therapeutics Discovery Division, University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA.
William J RayThe Neurodegeneration Consortium, Therapeutics Discovery Division, University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA.
The University of Texas MD Anderson Cancer Center · US

Funding

Alzheimer's Drug Discovery Foundation Grant 20160903, WJRRobert A. and Renee E. Belfer Family Foundation NA
6 · The paper itself

Abstract

Dual leucine zipper kinase (DLK, Map3k12) is an axonal protein that governs the balance between degeneration and regeneration through its downstream effectors c-jun N-terminal kinase (JNK) and phosphorylated c-jun (p-c-Jun). In peripheral nerves DLK is generally inactive until induced by injury, after which it transmits signals to the nucleus via retrograde transport. Here we report that in contrast to this mode of regulation, in the uninjured adult mouse cerebellum, DLK constitutively drives nuclear p-c-Jun in cerebellar granule neurons, whereas in the forebrain, DLK is similarly expressed and active, but nuclear p-c-Jun is undetectable. When neurodegeneration results from mutant human tau in the rTg4510 mouse model, p-c-Jun then accumulates in neuronal nuclei in a DLK-dependent manner, and the extent of p-c-Jun correlates with markers of synaptic loss and gliosis. This regional difference in DLK-dependent nuclear p-c-Jun accumulation could relate to differing levels of JNK scaffolding proteins, as the cerebellum preferentially expresses JNK-interacting protein-1 (JIP-1), whereas the forebrain contains more JIP-3 and plenty of SH3 (POSH). To characterize the functional differences between constitutive- versus injury-induced DLK signaling, RNA sequencing was performed after DLK inhibition in the cerebellum and in the non-transgenic and rTg4510 forebrain. In all contexts, DLK inhibition reduced a core set of transcripts that are associated with the JNK pathway. Non-transgenic forebrain showed almost no other transcriptional changes in response to DLK inhibition, whereas the rTg4510 forebrain and the cerebellum exhibited distinct differentially expressed gene signatures. In the cerebellum, but not the rTg4510 forebrain, pathway analysis indicated that DLK regulates insulin growth factor-1 (IGF1) signaling through the transcriptional induction of IGF1 binding protein-5 (IGFBP5), which was confirmed and found to be functionally relevant by measuring signaling through the IGF1 receptor. Together these data illuminate the complex multi-functional nature of DLK signaling in the central nervous system (CNS) and demonstrate its role in homeostasis as well as tau-mediated neurodegeneration.

Indexed as

AnimalsAxonsBrainHomeostasisJNK Mitogen-Activated Protein KinasesMaleMAP Kinase Kinase KinasesMAP Kinase Signaling SystemMiceMice, Inbred C57BLNeuronsSignal TransductionStress, PhysiologicalTranscriptomeJNK Mitogen-Activated Protein KinasesMAP Kinase Kinase Kinasesmitogen-activated protein kinase kinase kinase 12Alzheimer’s diseasecerebellumDLKMap3k12neurodegenerationsynaptic maintenancetau

Identifiers

PMID32659913
PMCPMC7402291
OpenAlexW3042108742

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.